Cipla Limited has informed the Exchange about Acquisition
CIPLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts more than Nifty 100 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Cipla Limited has signed definitive agreements to acquire a 100% stake in Inzpera Healthsciences Limited for a purchase consideration of approximately INR 110.65 crores (enterprise value of INR 120 crores), to be paid in cash. Inzpera, incorporated in 2016, is engaged in developing, manufacturing, and marketing differentiated paediatric pharmaceutical and wellness products in India. Upon completion, Inzpera will become a wholly owned subsidiary of Cipla. The acquisition is expected to close within one month. Inzpera's turnover has grown from INR 20.76 crores in FY23 to INR 26.75 crores in FY25, showing steady growth. The deal is not a related party transaction and no government or regulatory approvals are required.
This is a bolt-on acquisition that strengthens Cipla's presence in the paediatric pharmaceuticals and wellness segment, complementing its existing distribution network. At ~110 crores, the deal size is small relative to Cipla's scale, so financial impact is likely limited, but it signals strategic focus on expanding the paediatric portfolio.